VACC-4X + lenalidomide

VACC-4X + lenalidomide is an investigational **combination therapy** comprising VACC-4X, a therapeutic HIV vaccine made of synthetic peptides from conserved regions of the HIV-1 p24 capsid protein, and lenalidomide (marketed as Revlimid), an established immunomodulatory small molecule. This combination has been studied as a strategy to improve immunological function in people living with HIV who are receiving antiretroviral therapy (ART) but have not regained healthy CD4 T-cell counts. VACC-4X is designed to stimulate the immune system to target HIV-infected cells by enhancing specific T-cell responses, while lenalidomide amplifies immune activity through mechanisms including T-cell and cytokine modulation. Clinical studies have demonstrated that the combination increases CD4 counts beyond VACC-4X alone, is well tolerated, and appears to synergize the immunotherapeutic effects of the vaccine, supporting a "Boost & Kill" strategy for HIV functional cure research[1][2][3].

Other names

VACC-4x + Revlimid